TT232, a novel signal transduction inhibitory compound in the therapy of cancer and inflammatory diseases

Orsolya Szokolóczi, Richárd Schwab, István Peták, László Örfi, Ákos Pap, Alex N. Eberle, Tamás Szüts, György Kéri

Research output: Contribution to journalReview article

17 Citations (Scopus)


TT-232 is a structural analogue of somatostatin exhibiting strong and selective growth-inhibitory effects, inhibition of neurogenic inflammation, as well as general anti-inflammatory and analgesic potential without the wide-ranging endocrine side effects of the parent hormone and its "traditional" analogues. The anti-inflammatory action of TT-232 is mediated through the SSTR4 receptor, and its antitumor activity is mediated through the SSTR1 receptor and by the tumor-specific isoform of pyruvate kinase. Its mechanism of action is in line with a new era of molecular medicine called signal transduction therapy, where "false" intracellular or intercellular communication is inhibited or corrected without interfering with basic cell functions and machinery. TT232 has passed phase I clinical trials without toxicity and significant side effects, and phase II studies are running for oncological and anti-inflammatory indications, respectively. This compound has the perspective to become the first drug in molecularly targeted therapy of inflammation where a combined effect of anti-inflammatory, analgesic, and neurogenic inflammation-inhibiting activity can be achieved.

Original languageEnglish
Pages (from-to)217-235
Number of pages19
JournalJournal of Receptors and Signal Transduction
Issue number4-6
Publication statusPublished - Dec 1 2005


  • Analogue
  • Anti-inflammatory
  • Apoptosis
  • Clinical trial
  • Neurogenic inflammation
  • Signal transduction inhibitor
  • Somatostatin
  • TT232

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'TT232, a novel signal transduction inhibitory compound in the therapy of cancer and inflammatory diseases'. Together they form a unique fingerprint.

  • Cite this